Clicky

Akebia Therapeutics, Inc.(AKBA) News

Date Title
May 28 Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
May 27 Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
Mar 16 US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results
Mar 14 Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...
Mar 14 Q4 2024 Akebia Therapeutics Inc Earnings Call
Mar 13 Sector Update: Health Care Stocks Slipping Late Afternoon
Mar 13 Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Mar 13 Akebia Therapeutics: Q4 Earnings Snapshot
Mar 13 Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
Mar 11 Exploring High Growth Tech Stocks In The US Market
Jan 3 New Strong Sell Stocks for January 3rd
Oct 10 CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
Oct 9 Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
Oct 7 Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Sep 5 Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
Sep 2 Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Aug 26 Here's Why You Should Consider Buying Akebia (AKBA) Stock
Aug 2 Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
Jul 29 Akebia Therapeutics to Present at Upcoming Investor Conferences
Jun 24 Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer